A Phase 2, Multicenter, Open-label, Safety and Efficacy Study of XERMELO® (Telotristat Ethyl) Plus First-line Chemotherapy in Patients With Locally Advanced, Unresectable, Recurrent or Metastatic Biliary Tract Cancer (BTC)
- Abdelrahim, Maen (PI)
- Bernicker, Eric H. (Key Personnel)
- Chang, Jenny C. (Key Personnel)
- Darcourt, Jorge (Key Personnel)
- Heyne, Kirk (Key Personnel)
- Niravath, Polly A. (Key Personnel)
- Singh, Monisha (Key Personnel)
- Zhang, Jun (Key Personnel)
Project: Clinical Trial